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and higher QALYs. The results were robust to sensitivity analy-
ses. CONCLUSIONS: ETV is a dominant treatment option
across all populations in the treatment of patients with CHB,
compared to LVD and ADV. The results clearly suggest that sup-
pressing VL is economically attractive.
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OBJECTIVES: The risk of HIV, HBV and HCV transmission by
blood transfusion in sub Saharan Africa is (very) high compared
to the developed world. In this economic evaluation the cost-
effectiveness of interventions (donor management, quality of
testing, administration and additional tests) improving blood
transfusion safety is explored. METHODS: The residual risks of
HIV, HBV and HCV transmission were derived for Angola,
Benin, Botswana, Côte d’Ivoire, Ethiopia, Kenya, Mozambique,
Namibia, Rwanda, Uganda and Zambia from the Global Data-
base on Blood Safety (GDBS; WHO, 2004). Cost-effectiveness
ratios of the scenarios were determined by using a decision tree
combined with a Markov-model. Health gains and costs were
discounted by 3%. RESULTS: The CURRENT (current status)
scenario is cost-saving compared to the NONE (no screening, no
donor management) scenario, averting 2.0 million Disability
Adjusted Life Years (DALYs) and saving US$ 82 million annu-
ally. Over 94,000 new HIV infections are averted and 27,674
and 3360 new HBV and HCV infections respectively. Improving
the blood transfusion services from the CURRENT to the BEST
(100% screening, no errors) scenario shows a cost-effectiveness
ratio of 56.24 US$/DALY averted. With this step 2792 new HIV
infections are averted and 1723 and 1622 new HBV and HCV
infections respectively. In addition to the BEST scenario, HIV
p24 and HCV-antigen testing would avert 19 DALYs at annual
net costs of US$ 1.2 million (63,957 US$/DALY averted).
Extending the BEST scenario with single donation multiplex
NAT averts 60 DALYs at annual net costs of US$ 9.7 million
(161,051 US$/DALY averted). CONCLUSIONS: The current
level of blood transfusion safety provided in the included coun-
tries is cost-saving. However, maximizing the effects of donor
management and screening (coverage and errors) shows a favor-
able cost-effectiveness ratio. Introducing additional tests along-
side antibody testing is associated with high costs and limited
reduction of transmission risks.
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OBJECTIVE: The AIDS Pegasys Ribavirin International Coin-
fection Trial (APRICOT) demonstrated the efﬁcacy and safety of
peginterferon alfa-2a plus ribavirin (RBV) and interferon alfa plus
ribavirin (IFN/RBV) in patients co-infected with HIV-HCV.
However, the cost-effectiveness of treating CHC with peginter-
feron alfa-2a/RBV in this patient population has not assessed from
the Spanish National Health care System (NHS) perspective. The
objective was to establish the clinical prognosis, costs and cost-
effectiveness of peginterferon alfa-2a (180 mcg/week) plus RBV
versus IFN (3 million IU, three times a week) plus RBV, in patients
with HIV-HCV co-infection from a Spanish national health care
system (NHS) perspective. METHODS: A Markov model was
developed to simulate the disease progression of 40-year old
patients with HIV-HCV co-infection. Fibrosis progresión rates
were obtained from published studies. Efﬁcacy, in terms of sus-
tained virological response (SVR), for peginterferon alfa-2a plus
RBV and IFN/RBV in patients with genotype 1, genotypes 2/3
and genotypes 1/2/3 was obtained from APRICOT. Transition
probabilities and quality of life estimates were obtained from pub-
lished literature. Unit costs were obtained from a Spanish data-
base. Cost and outcomes were discounted by 3.5% annually.
RESULTS: In genotype 1 patients, peginterferon alfa-2a plus RBV
compared with IFN/RBV increases patientxs life expectancy by
1.27 years (0.77 quality-adjusted life years (QALYs)), yielding an
incremental cost-effectiveness ratio (ICER) of €3,677/life year
gained (LYG) (€6077/QALY gained). In genotypes 2/3 patients,
peginterferon alfa-2a plus ribavirin increases life expectancy by
4.63 years (2.33 QALYs), yielding an ICER of €569/LYG
(€1130/QALY gained). In genotypes 1/2/3 patients, the ICER is
€1487/LYG (€2762/QALY gained). CONCLUSIONS: From 
the Spanish NHS perspective, peginterferon alfa-2a (40KD)
(PEGASYS®) plus ribavirin (COPEGUS®) in patients with HIV-
HCV co-infection is a cost-effective treatment option, regardless
of HCV genotype.
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Chronic Hepatitis B (CHB) is caused by chronic infection with
Hepatitis B Virus (HBV) and represents a major global health
problem. Traditional CHB treatments are lamivudine (LAM) and
interferon alfa-2a (IFN). Peginterferon alfa-2a (PEG) has been
recently approved for the treatment of CHB disease. OBJEC-
TIVES: To assess the economic and clinical impact of the use of
peginterferon alfa-2a (40KD) versus LAM for the treatment of
HBeAg-negative CHB and versus IFN for the treatment of
HBeAg-positive CHB disease in Italy. METHODS: The CHB
disease course was simulated with the use of a Markov model.
The simulation was prolonged over a cohort’s lifetime. Com-
parative evaluation of PEG vs. LAM was based on a recent phase
III clinical trial in HBeAg-negative CHB. Comparative evalua-
tion of PEG vs. IFN was based on a phase II clinical trial com-
paring the two treatments in HBeAg-positive CHB. Considered
scenarios were: 48-week PEG vs LAM treatment; 48-week PEG
vs 4-year LAM; 24-week PEG vs. IFN. Clinical outcomes mea-
sured were average life years gained (LYs) and quality-adjusted
life years (QALYs). Direct costs were considered and valued
according to current Italian national prices, tariffs and published
literature. Deterministic and probabilistic sensitivity analyses
were performed and acceptability curves generated. Costs and
outcomes were discounted at a 3.5% annual rate. RESULTS:
0.82, 0.68, and 0.26 discounted QALYs per patient are gained
with PEG vs 48-week LAM, 4-year LAM and IFN, respectively.
Discounted incremental costs per patient are €7021, €5725, and
€2304. Corresponding cost-effectiveness and cost-utility ratios
are €9440/LY and €8603/QALY, €9218/LY and €8368/QALY,
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€9575/LY and €8714/QALY. CONCLUSIONS: The use of pegin-
terferon alfa-2a (40KD) in CHB patients, as compared with
current practice, has the potential of improving clinical outcomes
with a cost per LY and QALY gained below that of universally
accepted therapies.
PIN11
COST-EFFECTIVENESS OF OSELTAMIVIR FOR THE
TREATMENT OF INFLUENZA IN ADULTS AND CHILDREN IN
FINLAND
Järvinen A1, Joutseno J2, Gyldmark M3
1Helsinki University Hospital, Helsinki, Finland, 2Roche Oy, Espoo,
Finland, 3F Hoffmann La Roche, Basel, Switzerland
OBJECTIVE: To estimate the cost-effectiveness of oseltamivir in
the treatment of inﬂuenza in three different population groups
in Finland: Otherwise Healthy Adults aged 13-65 years (OHA);
Children aged 1-12 years (C); At-Risk Patients including elderly
≥65 years (ARP). METHODS: The cost-effectiveness of
oseltamivir vs symptomatic relief was compared using a deci-
sion–analytic model. Analyses were made both from the health-
care payer and the societal perspective. Health Outcomes
determined were days of normal activity and quality-adjusted life
years (QALY) gained. A life-time horizon was used to take
account of life-years lost due to mortality. Probabilities, utilities
and resource use data in the model were derived from published
Finnish population level trials and registers, from oseltamivir
clinical trials and from other published literature. A discount rate
of 5 % was applied. Unit costs were obtained from the 2001
Finnish Guidelines for Health Care Unit Cost converted to a
2005 level. Probabilistic Sensitivity Analysis was used to explore
the uncertainty around the base case means. RESULTS: The
mean cost from a health care payer perspective per day of normal
activity and per QALY gained respectively for the 3 different
population groups were: OHA €27/€12,008; C €14/€15,469;
ARP €7/€685. In OHA, oseltamivir is cost-saving when loss of
productivity is taken into account. CONCLUSION: The analy-
ses demonstrate that, in comparison with usual care, cost per
QALY gained with oseltamivir is below internationally accepted
thresholds. Oseltamivir is a cost-effective treatment for inﬂuenza
in all population groups (particularly in the ARP group) and is
cost-saving from a societal perspective in OHA. 
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OBJECTIVES: To assess the clinical effectiveness and costs of
teicoplanin or vancomycin use in acute hospital infections treat-
ment from service-provider perspective in Poland. METHODS:
Results of a systematic review of published clinical trials selected
in accordance with Cochrane Collaboration criteria were used
to assess effectiveness and safety. Systematic review was con-
ducted in April 2006; Medline (Pubmed) Cochrane and
EMBASE were searched. Only RCTs with credibility assessment
of 2 or more points according to Jadad scale were included in
the systematic review; relevant clinical data were pooled with
RevMan 4.2. Overall costs of treatment were taken into account;
pharmacotherapy and drug administration, drug monitoring,
patient monitoring and adverse events inﬂuenced the total cost
of treatment. CMA was used to assess savings from service-
provider perspective in case of cheaper drug use in clinical prac-
tice. Sensitivity analysis was made according to range of costs of
vancomycin generics available in Poland and number of days of
therapy. All calculations were performed for 2006 (1Euro =
3.8PLN). RESULTS: Nineteen relevant clinical trials with direct
comparison of teicoplanin and vancomycin were found. Clinical
effects of the drugs were similar and no signiﬁcant differences in
effectiveness were found in pooled data from RCTs. Teicoplanin
treatment was associated with higher costs of drug acquisition
compared to vancomycin (difference: 337PLN (€88.7) but Tar-
gocid occurred much cheaper referring to: drug level monitor-
ing, patient monitoring and administration costs. So, overall
treatment with teicoplanin occurred cheaper than vancomycin;
savings from service-provider perspective were: 743.3PLN
(€195.6) per therapy. CONCLUSIONS: Targocid treatment lead
to signiﬁcant savings for service-providers in average acute 
hospital infections treatment in Poland in comparison to 
vancomycin.
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OBJECTIVES: Comparative evaluation of two options for the
treatment of acute hepatitis C: immediate monotherapy of all
patients with (pegylated) interferon versus delayed combination
therapy of patients who do not experience spontaneous viral
clearance within three months after diagnosis with interferon
and ribavirin, and also a comparison between the applied
monotherapies for the immediate treatment option. METHODS:
Economic evaluation is based on three prospective nonrandom-
ized outcome studies. In two monotherapy studies (n = 128)
patients were treated with 5 million units of Interferon alfa-2b
daily during the ﬁrst 4 weeks and three times a week during the
following 20 weeks or with 1.5 μg/kg pegylated Interferon alfa-
2b weekly over a period of 24 weeks. In the combination therapy
study different dosages of interferon and ribavirin were admin-
istered. The evaluation focused on direct medical costs and
included physican’s fees, laboratory, as well as medication costs,
taking a societal perspective. Partial indirect costs were raised ex
post by enquiry of participants and physicians. Costs were
valued at 2002 market-prices. RESULTS: Monotherapy and
combination therapy of hepatitis C showed a similar high efﬁ-
cacy (sustained response rate: 87% vs. 90%). Patients in delayed
combination therapy study showed a quite high rate of sponta-
neous viral clearance of almost 50%. Direct medical costs of
immediate therapy (€7064/patient) were €321 lower than those
of delayed therapy (p = 0.8). Pegylated compared with unpegy-
lated interferon yielded €511 additional costs per patient (p =
0.01) in monotherapies. Considering the current genotype-
dependent therapy standard and the observed rate of sustained
responders, average costs per patient amounted to €10,848 and
were about 50% higher than costs of the immediate monother-
apy. Sensitivity analysis indicated a robust model. CONCLU-
SIONS: As there are no signiﬁcant differences in treatment
efﬁcacy, monotherapy seems to be slightly more cost-effective.
Medication is responsible for more than 90% of direct costs.
